This site uses modern web standards that aren't supported by your browser. For best results, please upgrade to Google Chrome, Microsoft Edge, or Mozilla Firefox.

Drug & Biologic Product Submissions

Drug & Biologic Product Submissions

National Drug Code (NDC) Assignment Guide

Drug Establishment Registration Reporting Requirements

Reed Tech SPL Solutions

Why Data Accuracy in Drug Listings is Essential

Every product on the market in the U.S. containing an active drug ingredient is required to be electronically drug listed with the FDA and assigned a National Drug Code (NDC). During this process, drug labelers submit complete electronic copies of the Content of...

Drug Product Annual Reporting Periods

Each company responsible for submitting drug product listings will have its own unique schedule for submission to FDA based on application approval dates and updates to labeling and listing information. However, FDA has established several specific reporting periods...

FDA’s Electronic Drug Listing Requirements for Manufacturers

If your company manufactures drug products for distribution in the United States, you probably know that you are required to register your establishment site(s) annually with FDA in Structured Product Labeling (SPL) format. Many manufacturers are unaware, however,...

National Drug Code (NDC) Assignment Guide eBook

One of the topics our team receives frequent questions about is National Drug Codes (NDCs). How are they structured? Where do they come from? What’s the difference between an NDC labeler code, product code and package code? To help industry members understand...

REMS in SPL Webinar

SPL expert Gary Saner discusses the FDA’s new initiative to receive Risk Evaluation and Mitigation Strategy (REMS) submissions in Structured Product Labeling...

4 Reasons to Submit REMS in SPL Now

As you may know, FDA recently began accepting Risk Evaluation and Mitigation Strategy (REMS) submissions in Structured Product Labeling (SPL) format. Although the FDA’s targeted date for acceptance was delayed slightly from September 2, the agency told us that it is...

FDA Drug Establishment Site Registration Webinar

SPL subject matter expert Jon Nolan gives an overview of the FDA’s requirements for registering Drug Establishment sites. Learn More: https://www.reedtech.com/products-services/life-sciences/structured-product-labeling-management Questions? Contact...

The Anatomy of a National Drug Code (NDC)

Part of the FDA’s requirement to electronically list drug products (Rx and OTC) includes the assignment of a National Drug Code (NDC). An NDC is a 10 digit number that uniquely identifies a drug product by stringing together three separate code segments. A complete...

FDA now accepting REMS in SPL format

Beginning today, September 2, 2016, the FDA is accepting REMS (Risk Evaluation and Mitigation Strategy) submissions in Structured Product Labeling (SPL) format. SPL is an XML document markup standard approved by Health Level 7 and previously adopted by the FDA for...

FDA UDI Enforcement

How will the FDA enforce the requirements of the UDI Final Rule? This video details what the FDA has said so far and what we can expect for UDI policing based on prior agency enforcement...

3 Options for Managing Biologic Lot Distribution Reports (LDR)

It is not new that the FDA requires the submission of Lot Distribution Reports (LDRs) for all products marketed in the U.S. under a Biologics License Application (BLA). However, it is important for BLA holders to know that a new FDA LDR submission format will soon be...

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close